Tscharre M, et al. - In patients admitted for stable coronary artery disease or acute coronary syndromes undergoing percutaneous coronary intervention, researchers evaluated the prognostic influence of clinically diagnosed familial hypercholesterolemia (FH) on long-term major adverse cardiovascular events (MACE) (a composite of all-cause death, myocardial infarction and ischemic stroke). They performed a mean follow-up for 6.0±2.4 years. They found that regardless of the common use of high-intensity statins, risk for long-term MACE in patients with probable or definite FH increased approximately 2-fold vs patients without FH, after adjustment for confounders. In patients with probable/definite FH, further improvement in clinical outcome might be achieved with PCSK9-inhibitors, along with other contemporary lipid lowering strategies.